Media-News

Be the most trusted biotech company

2023-07-27

HANQUYOU Marks 3rd Anniversary with Brilliant Achievements
2023-07-26

Henlius completed the phase 1/2 clinical trial of HLX04-O for the treatment of Ophthalmic Diseases
2023-07-17

Mr. Jason Zhu Succeeds as Chief Executive Officer and Mr. Wenjie Zhang Serves as Chairman of Henlius
2023-07-06

Henlius Welcomed SAB Member Alberto Mantovani to its Shanghai Innovation Centre
2023-07-03

Henlius Forecasts Profit in 2023 H1: Spurring a Seamless R&D, Manufacturing, and Commercialisation Positive Cycle
2023-06-28

Henlius Holds its 1st Overseas Scientific Advisory Board Meeting of 2023
2023-06-26

Henlius Immune Checkpoints Inhibitor Anti-CTLA-4 mAb Received IND Approval for the Treatment of HCC
2023-06-15

First Patient Dosed of Phase 2 Clinical Trial of Serplulimab in Combination with Innovative Anti-LAG-3 mAb for the Treatment of Metastatic Colorectal Cancer Patients
2023-06-12

Henlius Shines for Five Consecutive Years at BIO International Convention